To determine the role of pitavastatin for liver cancer prevention in HBV-infected individuals, we treated WT mice with 2 mg/kg pitavastatin or PBS alone (carrier control) once a week during the HBV+DEN liver carcinogenesis protocol until harvest, which suppressed IL-33 levels (Supplementary Fig. 7a). Here, IL33 is linked to liver cancer.